Skip to main content
. Author manuscript; available in PMC: 2021 Jun 1.
Published in final edited form as: Int Immunopharmacol. 2020 Mar 12;83:106378. doi: 10.1016/j.intimp.2020.106378

Figure 1.

Figure 1.

Mechanisms of TIGIT mediated suppression. TIGIT can block CD226-PVR mediated activation of T cells because it binds to CD226 with higher affinity than PVR (A). Ligation of TIGIT with PVR on naïve T cells blocks T cell priming, and triggers the production of the immunosuppressive molecule, FGL2 (B). Ligation of PVR with TIGIT promotes a regulatory dendritic cell that secretes IL-10 (C). Artwork by Ryan E. Lee.